Curcumin Nanoformulation for Pulmonary Drug Delivery

Document Type : Review

Authors

1 Doctoral Program in Biomedical Sciences, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

2 Department of Pharmacology and Pharmacy, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.

3 Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

4 Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

5 Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Abstract

Curcumin has various beneficial effects on human health, but its efficacy is yet to be proven in clinical trials. Curcumin has poor bioavailability, low solubility, and rapid metabolism which become the principal reasons behind the lack of curcumin efficiency in clinical trials. This review aimed to focus on nanotechnologies to improve the bioavailability of curcumin inhalation formulations. Many studies were done to improve curcumin's bioavailability by administering through nanoparticle drug carriers. Pulmonary drug delivery has some advantages such as giving a rapid onset of action and bypassing the first hepatic metabolism. Lungs also have a large area for absorption. So far, there are various methods to produce curcumin nanoformulations that are proper, stable, and effective, and are suitable to enhance curcumin pulmonary delivery in the form of liposomes, polymeric and solid lipid nanoparticles, nano suspensions, and cyclodextrin formulations. Therefore, analysis of the various methods, to conclude the best method for curcumin pulmonary delivery is needed. In conclusion, the best method to make nanocurcumin formulation is the one that gives the most advantage and lowest toxicity. Therefore the best choices for curcumin nanoformulations are curcumin nanosuspension and cyclodextrin formulated nanocurcumin/proliposomes.

Keywords

Main Subjects

References

  • Rathore S, Mukim M, Sharma P, Devi S, Nagar JC, Khalid M. Curcumin a review for health benefits. Int J Inf Res Rev. 2020; 7(1): 273–2
  • Karthikeyan A, Senthil N, Min T. Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol. 2020; 11: 487–511.
  • Chang WA, Chen CM, Sheu CC, Liao SH, Hsu YL, Tsai MJ, Kuo PL. The potential effects of curcumin on pulmonary fibroblasts of idiopathic pulmonary fibrosis (IPF)-approaching with next-generation sequencing and bioinformatics. 2020; Article ID 5458.
  • Ahmad RS, Hussain MB, Sultan MT, Arshad MS, Waheed M, Shariati MA, Plygun S, Hashempur MH. Biochemistry, safety, pharmacological activities, and clinical applications of turmeric: a mechanistic review. Evid Based Complement Alternat Med. 2020; Article ID 7656919.
  • Shaikh SB, Bhandary YP. Effect of curcumin on IL-17A mediated pulmonary AMPK kinase/cyclooxygenase-2 expressions via activation of NFkappaB in bleomycin-induced acute lung injury in vivo. Int Immunopharmacol. 2020; Article ID 106676.
  • Hu Y, Li M, Zhang M, Jin Y. Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles. Int J Pharm. 2018; 551(1–2): 212–2
  • Lelli D, Sahebkar A, Johnston TP, Pedone C. Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacol Res. 2017; 115: 133–1
  • Hemmati AA, Sistani Karampour N, Dahanzadeh S, Sharif Makhmalzadeh B, Rezaie A, Ghafourian M. The protective effects of nebulized nano-curcumin against bleomycin-induced pulmonary fibrosis in rats. Jundishapur J Nat Pharm Prod. 2021; 16(2): 1–7.
  • Subramani PA, Narala VR. Challenges of curcumin bioavailability novel aerosol remedies. Nat Prod Commun. 2013; 8(1): 121–12
  • Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853(1–2): 183–18
  • Cazzola M, Cavalli F, Usmani OS, Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020; 17(5): 635–6
  • Javadzadeh Y, Yaqoubi S. Therapeutic nanostructures for pulmonary drug delivery. In: Andronescu E, Grumezescu AM, Eds. Nanostructures for drug delivery. Philadelphia: Elsevier, 2017.
  • Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015; 8: 131–13
  • Verma RK, Ibrahim M, Garcia-Contreras L. Lung anatomy and physiology and their implications for pulmonary drug delivery. In: Nokhodchi A, Martin GP, Eds. Pulmonary drug delivery advances and challenges. Chichester: Wiley, 2015.
  • Newman PS. Drug delivery to the lungs challenges and opportunities. Ther Deliv. 2017; 8(8): 647–6
  • Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J Antimicrob Chemother. 2015; 70(11): 2945–29
  • Chandel A, Goyal AK, Ghosh G, Rath G. Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019; Article ID 108601.
  • Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015; 219: 500–5
  • Yo EC, Kadharusman MM, Karman AP, Louisa M, Arozal W. Potential pharmacological options and new avenues using inhaled curcumin nanoformulations for treatment of post COVID-19 fibrosis. Sys Rev Pharm. 2021; 12(1): 1119–11
  • Babaei F, Nassiri M, Hosseinzadeh H. Curcumin (a constituent of turmeric): new treatment option against COVID-19. Food Sci Nutr. 2020; 8(10): 5215–52
  • Subramani PA, Panati K, Narala VR. Curcumin nanotechnologies and its anticancer activity. Nutr Cancer. 2017; 69(3): 381–3
  • Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 2018; 8(3): 440–44
  • Muneer S, Masood Z, Butt S, Anjum S, Zainab H, Anwar N, Ahmad N. Proliposomes as pharmaceutical drug delivery system: a brief review. J Nanomed Nanotechnol. 2017; 8(3): 1–5.
  • Adel IM, ElMeligy MF, Abdelrahim MEA, Maged A, Abdelkhalek AA, Abdelmoteleb AMM, Elkasabgy NA. Design and characterization of spray-dried proliposomes for the pulmonary delivery of curcumin. Int J Nanomedicine. 2021; 16: 2667–2687.
  • Carvalho SR, Watts AB, Peters JI, Williams RO. Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges. In: Nokhodchi A, Martin GP, Eds. Pulmonary drug delivery advances and challenges. Chichester: Wiley, 2015.
  • El-Sherbiny IM, Smyth HD. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol Pharm. 2012; 9(2): 269–2
  • Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci. 2020; Article ID 587997.
  • Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, Liu H, Cui D, Chen Y, Wang S. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine. 2012; 7: 3667–36
  • Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020; 24(1): 1–16.
  • Hu L, Kong D, Hu Q, Gao N, Pang S. Evaluation of high-performance curcumin nanocrystals for pulmonary drug delivery both in vitro and in vivo. Nanoscale Res Lett. 2015; 10(1): 1–9.
  • Haimhoffer Á, Rusznyák Á, Réti-Nagy K, Vasvári G, Váradi J, Vecsernyés M, Bácskay I, Fehér P, Ujhelyi Z, Fenyvesi F. Cyclodextrins in drug delivery systems and their effects on biological barriers. Sci Pharm. 2019; 87(4): 1–21.
  • John MK, Xie H, Bell EC, Liang D. Development and pharmacokinetic evaluation of a curcumin co solvent formulation. Anticancer Res. 2013; 33(10): 4285–42
  • Wang Y, Wang C, Zhao J, Ding Y, Li L. A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability. J Colloid Interface Sci. 2017; 485: 91–9
  • Kurniawansyah F, Mammucari R, Foster NR. Inhalable curcumin formulations by supercritical technology. Powder Technol. 2015; 284: 289–2
  • Sandersen C, Bienzle D, Cerri S, Franck T, Derochette S, Neven P, Mouytis-Mickalad A, Serteyn D. Effect of inhaled hydrosoluble curcumin on inflammatory markers in broncho-alveolar lavage fluid of horses with LPS-induced lung neutrophilia. Multidiscip Respir Med. 2015; 10(1): 1–8.
  • Zhang B, Swamy S, Balijepalli S, Panicker S, Mooliyil J, Sherman MA, Parkkinen J, Raghavendran K, Suresh MV. Direct pulmonary delivery of solubilized curcumin reduces severity of lethal pneumonia. FASEB J. 2019; 33(12): 13294–13
Research Journal of Pharmacognosy
Volume 9, Issue 4
October 2022
Pages 73-81

Files

Share

How to cite

Statistics